View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-reports-third-quarter-2025-financial-results-and-recent ...

– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU ™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME program ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-reports-third-quarter-2025-financial-results-and-recent ...

Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine ...

– FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients – – FREEDOM2-DM1 5 mg/kg cohort on track to readout in Q1 2026, with all patients ...

Huntsman Cancer Institute at the University of Utah (the U) faculty and staff continue to set new standards in cancer research, clinical innovation, and community engagement. The faculty and staff’s ...